Compare BridgeBio Pharma Inc (BBIO) vs Essex Property Trust, Inc. (ESS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Essex Property Trust, Inc. — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.27B), while Essex Property Trust, Inc. trades at $297.8 (market cap $19.12B). The key difference: Essex Property Trust, Inc. is the larger of the two by market cap, and Essex Property Trust, Inc. pays a 3.48% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | ESS | |
|---|---|---|
Market Cap | $16.27B | $19.12B |
Sector | Health | Real Estate |
52-Week High | $90.17 | $298.33 |
52-Week Low | $44.81 | $239.61 |
Enterprise Value | $17.82B | $25.84B |
Dividend Yield | — | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →
